Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lifestance Health (LFST)

LifeStance raises 2025 Adjusted EBITDA outlook as Q2 revenue rises 11% to $345.3 million

Positive Impact 4 of 5 earnings Written later

LifeStance Health Group reported second-quarter 2025 revenue of $345.3 million, up 11% from a year earlier, and a net loss of $3.8 million, narrowed from $23.3 million. The company reiterated its full-year 2025 revenue outlook of $1.40 billion to $1.44 billion and raised its full-year Adjusted EBITDA and Center Margin expectations.

Key points

  • Q2 revenue was $345.3 million, up 11% from $312.3 million; visit volumes rose 12% to 2.2 million.
  • Net loss was $3.8 million versus $23.3 million a year earlier; Adjusted EBITDA rose 19% to $34.0 million.
  • Full-year 2025 Adjusted EBITDA raised to $140 million to $150 million; Center Margin raised to $441 million to $465 million.
  • Third-quarter 2025 revenue is expected at $345 million to $365 million.

The filing

CompanyLifestance Health (LFST)
Form8-K, current report
Filed with the SECAug 6, 2025, 7:03 PM ET
Accession number0000950170-25-104363

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.